medigraphic.com
ISSN 1527-3172 (Electronic)

2015, Number 1

<< Back Next >>

MEDICC Review 2015; 17 (1)

HPLC for confirmatory diagnosis and biochemical monitoring of cuban patients with hyperphenylalaninemias

Contreras RJ, Alonso JE, Fuentes SLE

Language: English
References: 49
Page: 23-28
PDF size: 161.28 Kb.


ABSTRACT

INTRODUCTION Hyperphenylalaninemias are inborn errors of phenylalanine metabolism caused by deficiency of L-phenylalanine hydroxylase (the enzyme that converts phenylalanine to tyrosine), resulting in increased serum phenylalanine (› 4 mg/dL or 240 µmol/L). Phenylketonuria, or PKU, is the most common form. Untreated PKU is associated with progressive neurodevelopmental delay, evolving towards intellectual impairment.
Cuba introduced a national newborn screening program for PKU in 1986. It has enabled early diagnosis and initiation of dietary treatment, reducing appearance of intellectual impairment in these patients. Originally, confirmatory diagnosis was done only by quantifying serum phenylalanine. In 2010, however, an HPLC method for quantifying serum phenylalanine and tyrosine simultaneously was validated at the National Medical Genetics Center, to perform confirmatory and differential diagnosis of hyperphenylalaninemias, as well as biochemical monitoring of patients diagnosed.
OBJECTIVE Create birth weight percentile distribution tables and curves for neonates by gestational age and sex in Holguín Municipality, capital of the eastern Cuban province of the same name.
METHODS A descriptive retrospective case-series study was conducted from June 2010 through June 2012. The study population comprised 531 infants who tested positive in the National Neonatal Screening Program for Phenylketonuria. Variables used were serum phenylalanine concentration (first criterion of positivity) and tyrosine, phenylalanine/tyrosine ratio (second criterion, both detected by reverse-phase HPLC with direct fluorescence), hyperphenylalaninemia classification, year of diagnosis, sex, and province of origin.
RESULTS Of the samples, 97.7% (519/531) were confirmed as false positives, and 10.4% (55/531) had transient neonatal tyrosinemia. Hyperphenylalaninemia was diagnosed in 12 infants (2.2%): 1.3% (7/531) presented classical PKU, with 34.7 ± 14.7 mg/dL phenylalanine in serum and phenylalanine/tyrosine ratio of 18.9 ± 12.7; and 0.9% (5/531) had persistent hyperphenylalaninemia, with 8.9 ± 3.4 mg/dL of phenylalanine and phenylalanine/tyrosine ratio of 4.5 ± 1.6. Matanzas Province contributed more cases than any of Cuba's 14 other provinces (3/12, 25%) and there was a slight predominance of male sex (7/12, 58.3%). During biochemical monitoring, 83.3% of patients (10/12) reduced their levels of phenylalanine (≤ 5 mg/dL or 300 µmol/L): 5 with classical PKU and all 5 with persistent hyperphenylalaninemia. The incidence of neonatal hyperphenylalaninemias was 1/22,503 live births and 1/38,577 for classical PKU.
CONCLUSIONS HPLC for simultaneous quantification of phenylalanine and tyrosine in serum meets the needs of a confirmatory test for patients testing positive in Cuba's National Neonatal Screening Program for Phenylketonuria (which has high false positive rates). It has enabled introduction in Cuba of a second PKU diagnostic criterion of positivity for both the classification of hyperphenylalaninemias and the biochemical monitoring of diagnosed patients.


REFERENCES

  1. Belmont-Martínez L, Fernández-Lainez C, Ibarra-González I, Guillén-López S, Monroy- Santoyo S, Vela-Amieva M. Evaluación bioquímica de la fenilcetonuria (PKU): del diagnóstico al tratamiento. Acta Pediatr Méx. 2012 Nov– Dec;33(6):296–300. Spanish.

  2. Mitchell JJ. Phenylalanine Hydroxylase Defi - ciency. In: Pagon RA, Adam MP, Bird TD, editors. GeneReviews™ [Internet]. 2010 Jan 10 [updated 2013 Jan 31; cited 2014 Jan]. Seattle (WA): University of Washington; 1993–2014. Available from: http://www.ncbi.nlm.nih.gov/books/ NBK1504/

  3. Gutiérrez García E, Barrios García B, Damiani Rosell A. Estudio de prevalencia de la fenilcetonuria en una muestra de niños con retraso mental. Rev Cubana Ped. 1989;61(1):94–8. Spanish.

  4. Scriver C, Kaufman S. The hyperphenylalaninemias. In: Scriver C, Beaudet AL, Sly WS, Barton C, Valle D, Kinsler KW, et al, editors. The metabolic and molecular bases of inherited disease. 8th ed. Vol II. New York: McGraw-Hill; 2001. p. 1667–724.

  5. Cornejo V, Raimann E. Errores innatos del metabolismo de los aminoácidos: Hiperfenilalaninemias. In: Colombo M, Cornejo V, Raimann E, editors. Errores innatos en el metabolismo del niño. 1st ed. Santiago de Chile: Editorial Universitaria; 1999. p. 59–65. Spanish.

  6. Smith I, Philip L. The hyperphenylalaninemias. In: Fernandes J, Saudubray JM, Van den Berghe G, editors. Inborn metabolic diseases, diagnosis and treatment. 3rd ed. Heidelberg (DE): Springer- Verlag; 2000. p. 171–83.

  7. Martínez Rey L. Las Hiperfenilalaninemias. Recomendaciones para el Genetista Clínico. Havana: Editorial Ciencias Médicas; 2006. 49 p. Spanish.

  8. Ramírez-Farías MC, Pérez-Andrade ME, Ibarra- González I, Vela-Amieva M. Controversias en la clasifi cación de las hiperfenilalaninemias. Propuesta de unifi cación. Acta Ped Méx. 2007;28(6):261–9. Spanish.

  9. Marcos Plasencia LM, Pérez Torres AJ, González Cabrera B, Tamayo Chong V. Actuali dad de la fenilcetonuria en Cuba. Avances Méd Cuba. 2002;33:12–6. Spanish.

  10. Borrajo G. Panorama epidemiológico de la fenilcetonuria en Latinoamérica. Acta Ped Méx. 2012;33(6):279–87. Spanish.

  11. Cornejo V, Manríquez V, Colombo M, Mabe P, Jiménez M, de la Parra A, et al. Fenilcetonuria diagnosticada en período neonatal y lactancia materna. Rev Méd Chile. 2003 Nov;131(11):1280–7. Spanish.

  12. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963 Sep;32:338–43.

  13. Heredero L, Atencio G, Vega JL, Gutiérrez E, Damiani A. Diagnóstico precoz de fenilcetonuria en Cuba. Rev Cuba Pediatr. 1986 Jan– Feb;58(1):27–33. Spanish.

  14. Martínez Rey L, Robaina Jiménez Z, García Izquierdo S, Gutiérrez García E. Resultados Clínico-Sociales del Programa Cubano de Pesquisa Neonatal de Fenilcetonuria durante 20 años. Rev Cub Genet Comun [Internet]. 2008 Jan–Apr [cited 2014 Aug 10];2. Available from: http://bvs.sld.cu/revistas/rcgc/v2n1/ rcgc07108%20.htm. Spanish.

  15. TecnoSuma Internacional, S.A. UMTEST® PKU [Internet]. Havana: Immunoassay Center (CU); 2004 Apr 20 [cited 2014 Mar 10]. 11 p. Available from: http://www.tecnosuma.com/ Informacion/Inserts%20(PDF)/UMTEST%20 PKU.pdf. Spanish.

  16. Singh R, Rohr F, Frazier D, Cunningham A, Modifi S, Ogata B, et al. Recommendations for the nutrition management of phenylalanine hydroxylase defi ciency. Genetics Med. 2014 Feb;16(2):121–31.

  17. Drnevich D, Vary TC. Analysis of physiological amino acids using dabsyl derivatization and reversed-phase liquid chromatography. J Chromatogr. 1993 Mar 5;613(1):137–44.

  18. Madira WM, Xavier F, Stern J, Wilcox AH, Barron JL. Determination and assessment of the stability of phenylalanine and tyrosine in blood spots by HPLC. Clin Chem. 1992 Oct;38(10):2162–3.

  19. Kok WT, Brinkman UA, Frei RW. Rapid determination of phenylalanine and tyrosine in urine and serum by HPLC with electrochemical detection. J Pharm Biomed Anal. 1983;1(3):369–72.

  20. Malaver Ortega LF, Alméciga-Díaz CJ, Morales Monsalve IS, Echeverri Peña OY, Guevara Morales J, Zuluaga Torres E, et al. Cuantifi cación de aminoácidos en plasma empleando Cromatografía Líquida de Alta Efi ciencia. Acta Bioquím Clín Latinoam. 2009 Oct–Dec;43(4):647–61. Spanish.

  21. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993 Jan;39(1):66–71.

  22. Qu Y, Slocum R, Fu J, Rasmussen WE, Rector HD, Miller JB, et al. Quantitative amino acid analysis using a Beckman system gold HPLC 126AA analyzer. Clin Chim Acta. 2001 Oct;312(1– 2):153–62.

  23. Bartolomeo MP, Maisano F. Validation of a reversed-phase HPLC method for quantitative amino acid analysis. J Biomol Tech. 2006 Apr;17(2):131–7.

  24. Frank MP, Powers RW. Simple and rapid quantitative high-performance liquid chromatographic analysis of plasma amino acids. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1–2):646–9.

  25. Gatti R, Gioia MG. Liquid chromatographic fl uorescence determination of amino acids in plasma and urine after derivatization with phanquinone. Biomed Chromatogr. 2008 Feb;22(2):207–13.

  26. Kandar R, Zakova P. Determination of phenylalanine and tyrosine in plasma and dried blood samples using HPLC with fl uorescence detection. J Chromatography B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3926–9.

  27. Fuentes LE, Contreras J, Alonso E, Martínez L. Punto de corte óptimo para el diagnóstico confi rmatorio de hiperfenilalaninemias por HPLC. Rev Cub Gen Com [Internet]. 2014 [cited 2014 Sep 15];8(1). Available from: http://bvs.sld.cu/revis tas/rcgc/v8n1/rcgc050144.html. Spanish.

  28. Contreras J, Alonso E, Fuentes LE, Gandarilla A. Relación fenilalanina/tirosina en niños sanos y con hiperfenilalaninemias en Cuba. Rev Cub Gen Com [Internet]. 2012 [cited 2014 Sep 15];6(2). Available from: http://bvs.sld.cu/revis tas/rcgc/v6n2/rcgc050212.html. Spanish.

  29. National Health Statistics and Medical Records Division (CU). Anuarios Estadísticos de Salud 2010–2012 [Internet]. 2012 [cited 2013 Jan 15]. Available from: www.sld.cu/sitios/dne/. Spanish.

  30. Contreras J, Alonso E, Camayd I, Hernández O, de la Peña D, Nogueras L. Tirosinemia neonatal transitoria: diagnóstico bioquímico de un caso. Rev Cub Gen Com [Internet]. 2012 [cited 2014 Sept 15];6(1):[about 3 screens]. Available from: http://bvs.sld.cu/revistas/rcgc/v6n1/rcgc100112 .html. Spanish.

  31. Campistol J, Gassió R, Artuch R, Vilaseca MA; PKU Follow-up Unit. Neurocognitive function in mild hyperphenylalaninemia. Dev Med Child Neurol. 2011 May;53(5):405–8.

  32. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010 Oct 23;376(9750):1417–27.

  33. Arcos-Correa JH, Vela-Amieva M. El paciente adulto con fenilcetonuria: un nuevo reto para el médico internista en México. Med Int Mex. 2012 May–Jun;28(3):256–61. Spanish.

  34. Vela Amieva M, Ibarra González I, Monroy Santoyo S, Fernández Laínez C, Guillén López S, Belmont Martinez L, et al. Modelo de atención inicial de la fenilcetonuria y otras hiperfenilalaninemias en el Instituto Nacional de Pediatría. Acta Pediatr Méx. 2010 Nov–Dec;31(6):297–303. Spanish.

  35. Marcos Plasencia LM. Soporte alimentario, nutrimental y metabólico de los fenilcetonúricos en Cuba [thesis]. [Havana]: University of Medical Sciences of Havana; 2010. Spanish.

  36. Campos D. Tamiz de los errores innatos del metabolismo por espectrometría de masas en tándem: principales biomarcadores. Rev Méd Chile. 2011 Oct;139(10):1356–64. Spanish.

  37. A Laboratory Guide to Newborn Screening in the UK for phenylketonuria [Internet]. London: Public Health England; 2011 Apr 4 [cited 2013 Jan 15]. Available from: http://newbornbloodspot.screen ing.nhs.uk/pku-supportingdocs#fi leid11844

  38. Cunningham GC, Lorey F, Arnopp J, Patterson M, Currier R. Early discharge trends and their effect on PKU screening. In: Pass K, Levy H, editors. Early hospital discharge: Impact on newborn screening. Council of Regional Networks for Genetics Services; March 31, 1995. Atlanta: Emory University School of Medicine; 1995. p. 31–56.

  39. Marrero-González N, González-Reyes EC, Frómeta-Suárez A, Baloy-Nodarse A, Castells- Martínez E, Pérez-Morás PL, et al. Infl uencia de la edad en los resultados del cribado neonatal de hipotiroidismo congénito, fenilcetonuria y galactosemia. Rev Latinoamer Patol Clin. 2004 Oct– Dec;51(4):220–5. Spanish.

  40. Blau N, Hennermann J, Langenbeck U, Lichter- Konecki U. Diagnosis, classifi cation and genetics of phenylketonuria and tetrahydrobiopterin (BH4) Defi ciencies. Mol Genet Metab. 2011;104 Suppl:S2–9.

  41. Cedillo Carvallo B, Estrada Gómez RA, Jonguitud Díaz V, Parra Ortega I. Factores que afectan algunas de las pruebas del tamiz neonatal. Med Univer. 2007 Jan–Mar;9(34):3–6. Spanish.

  42. Harrison TR. Trastornos del metabolismo. Trastornos hereditarios del metabolismo de los aminoácidos. In: Braunwald E, Isselbacher KJ, Peterdosdorf RG, Wilson JD, Martin JB, Fauci AS, editors. Principios de medicina interna. 7th ed. México. D.F: Interamerican McGraw-Hill; 1989. p.1967–72. Spanish.

  43. Cerone R, Caruso U, Schiaffi no MC, Gazzolo A, Barella C, Romano C. Early newborn screening for phenylketonuria: phenylalanine levels during the fi rst 24 hours of life. In: Levy HL, Hermos RJ, Grady GF, editors. Proceedings of the Third Meeting of The International Society for neonatal screening; 1996 Oct 20–23; Boston, Massachusetts. New England: Regional Newborn Screening Program; 1996. p. 293–4.

  44. Marrero-González N, Frometa Suárez A, Coto R, Villegas L. Medición de TSH, T4 y Phe en muestras de sangre del cordón umbilical en papel de fi ltro: impacto en el tamizaje neonatal. Biomédica. 2000;20(1):33–4. Spanish.

  45. Pontón RA. Errores congénitos del metabolismo: tirosinemias. INVENIO. 2004 Jun;7(12):117–26. Spanish.

  46. Burgos LC, Manotas RJ. Tirosinemia neonatal. IATREIA. 1995 Dec;8(4):147–9. Spanish.

  47. Scriver C, Kaufman S. Hypertyrosinemia. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. Vol II. New York: McGraw-Hill; 2001. p. 1777–806.

  48. Torres-Sepúlveda MR, Martínez de Villareal LE, González Alanis R, Ruíz Herrera C. Tamiz metabólico neonatal por espectrometría de masas en tándem: dos años de experiencia en Nuevo León, México. Salud Pública Méx. 2008 May–Jun;50(3):200–6. Spanish.

  49. Zschocke J, Haverkamp T, Birk Moller L. Clinical utility gene card for Phenylketonuria. Eur J Hum Genet [Internet]. 2012 Feb [cited 2013 Jan 14];20(2). Available from: www.nature.com/ejhg/ journal/v20/n2/full/ejhg2011172a.html




2020     |     www.medigraphic.com